Title:
SALT, SOLVATE, AND CRYSTAL OF COMPOUND HAVING EP2 ANTAGONISTIC ACTIVITY
Document Type and Number:
WIPO Patent Application WO/2022/138792
Kind Code:
A1
Abstract:
The purpose of the present invention is to provide a suitable form for a compound, and an active pharmaceutical ingredient thereof, for the prevention and/or treatment of a disease associated with the activation of an EP2 receptor, said compound having an antagonistic activity on an EP2 receptor. Provided is a compound I having antagonistic activity on an EP2 receptor. Also provided are crystals of the compound I disclosed in the present invention, salts of the compound I, and solvates and crystal forms thereof serving as an active pharmaceutical ingredient.
Inventors:
OTANI SHUHEI (JP)
FUJITO TAKAYUKI (JP)
NISHIUMA NAOKI (JP)
FUJITO TAKAYUKI (JP)
NISHIUMA NAOKI (JP)
Application Number:
PCT/JP2021/047770
Publication Date:
June 30, 2022
Filing Date:
December 23, 2021
Export Citation:
Assignee:
ONO PHARMACEUTICAL CO (JP)
International Classes:
C07C235/56; A61K31/196; A61K39/395; A61K45/00; A61P1/00; A61P9/10; A61P9/12; A61P11/06; A61P13/10; A61P13/12; A61P15/08; A61P17/10; A61P19/02; A61P19/06; A61P21/00; A61P25/02; A61P25/04; A61P25/16; A61P25/28; A61P29/00; A61P35/00; A61P35/02; A61P37/06; A61P37/08; A61P43/00
Domestic Patent References:
| WO2005080367A1 | 2005-09-01 | |||
| WO2020262603A1 | 2020-12-30 |
Foreign References:
| JP2015520738A | 2015-07-23 | |||
| JP2014533713A | 2014-12-15 | |||
| JP2012140435A | 2012-07-26 |
Attorney, Agent or Firm:
SAEGUSA & PARTNERS (JP)
Download PDF:
Previous Patent: EP2 ANTAGONIST
Next Patent: COMBINATION BETWEEN EP2 RECEPTOR ANTAGONIST AND IMMUNE CHECKPOINT INHIBITOR AND/OR EP4 RECEPTOR ANTA...
Next Patent: COMBINATION BETWEEN EP2 RECEPTOR ANTAGONIST AND IMMUNE CHECKPOINT INHIBITOR AND/OR EP4 RECEPTOR ANTA...